Plasma Proteome–Based Test for First-Line Treatment Selection in Metastatic Non–Small Cell Lung Cancer

Petros Christopoulos; Michal Harel; Kimberly McGregor; Yehuda Brody; Igor Puzanov; Jair Bar; Yehonatan Elon; Itamar Sela; Ben Yellin; Coren Lahav; Shani Raveh; Anat Reiner-Benaim; Niels Reinmuth; Hovav Nechushtan; David Farrugia; Ernesto Bustinza-Linares; Yanyan Lou; Raya Leibowitz; Iris Kamer; Alona Zer Kuch; Mor Moskovitz; Adva Levy-Barda; Ina Koch; Michal Lotem; Rivka Katzenelson; Abed Agbarya; Gillian Price; Helen Cheley; Mahmoud Abu-Amna; Tom Geldart; Maya Gottfried; Ella Tepper; Andreas Polychronis; Ido Wolf; Adam P. Dicker; David P. Carbone; David R. Gandara

Journal ArticleOPEN ACCESS

Plasma Proteome–Based Test for First-Line Treatment Selection in Metastatic Non–Small Cell Lung Cancer

Christopoulos P
Harel M
McGregor K
et al.

JCO Precision Oncology (2024) (8)

DOI: 10.1200/po.23.00555

1Citations

21Readers

Get full text

Abstract

PROphet blood test supports first-line immunotherapy treatment decisions for patients with metastatic NSCLC.

Cite

CITATION STYLE

APA

Christopoulos, P., Harel, M., McGregor, K., Brody, Y., Puzanov, I., Bar, J., … Gandara, D. R. (2024). Plasma Proteome–Based Test for First-Line Treatment Selection in Metastatic Non–Small Cell Lung Cancer. JCO Precision Oncology, (8). https://doi.org/10.1200/po.23.00555

Plasma Proteome–Based Test for First-Line Treatment Selection in Metastatic Non–Small Cell Lung Cancer

Abstract

Cite

Register to see more suggestions